Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Non-Hodgkin × Histamine Antagonists × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Urinary Bladder Neoplasms 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Medulloblastoma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia, Hairy Cell 1 Fallopian Tube Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Ependymoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma in Situ 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Rituximab 305 Cyclophosphamide 287 Etoposide 125 fludarabine phosphate 124 Peripheral Blood Stem Cell Transplantation 107 fludarabine 104 Filgrastim 103 Melphalan 91 Mycophenolic Acid 87 Whole-Body Irradiation 80 Vincristine 80 Cytarabine 77 Busulfan 77 Doxorubicin 71 Radiotherapy 70 Prednisone 67 Cyclosporine 67 Tacrolimus 64 Bendamustine Hydrochloride 61 Methotrexate 56 Granulocyte Colony-Stimulating Factor 56 Antilymphocyte Serum 50 Carmustine 48 Dexamethasone 44 Gemcitabine 42 Lenalidomide 41 venetoclax 39 Bortezomib 35 obinutuzumab 33 ibritumomab tiuxetan 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00719472 2017-05-15

RATE

Genentech, Inc.

Phase 3 Completed

451 enrolled 11 charts

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡